You just read:

Faster-acting insulin aspart versus NovoRapid® (insulin aspart) in a basal-bolus regimen: significantly reduces HbA1c in type 1 diabetes and has a comparable HbA1c reduction in type 2 diabetes

News provided by

Novo Nordisk

13 Jun, 2016, 15:00 BST